Investments
116Portfolio Exits
48Partners & Customers
1Latest BVF Partners News
Nov 28, 2023
PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a clinical stage biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced it has secured $41.5M in a Series B funding round. The round was led by Cowen Healthcare Investments, with participation from existing investors from Aro’s Series A financing round in 2020, including Johnson & Johnson Innovation – JJDC, Inc. (JJDC), Northpond Ventures, Healthcap and BVF Partners, L.P. In conjunction with
BVF Partners Investments
116 Investments
BVF Partners has made 116 investments. Their latest investment was in Forward Therapeutics as part of their Series A on November 11, 2023.
BVF Partners Investments Activity
Date | Round | Company | Amount | New? | Co-Investors | Sources |
|---|---|---|---|---|---|---|
11/8/2023 | Series A | Forward Therapeutics | $50M | Yes | OrbiMed Advisors, RA Capital Management, and Undisclosed Investors | 4 |
10/5/2023 | PIPE | SAB Biotherapeutics | Yes | 2 | ||
9/6/2023 | Series G | Nimbus Therapeutics | $210M | No | 2 | |
9/5/2023 | PIPE | |||||
8/2/2023 | Series F |
Date | 11/8/2023 | 10/5/2023 | 9/6/2023 | 9/5/2023 | 8/2/2023 |
|---|---|---|---|---|---|
Round | Series A | PIPE | Series G | PIPE | Series F |
Company | Forward Therapeutics | SAB Biotherapeutics | Nimbus Therapeutics | ||
Amount | $50M | $210M | |||
New? | Yes | Yes | No | ||
Co-Investors | OrbiMed Advisors, RA Capital Management, and Undisclosed Investors | ||||
Sources | 4 | 2 | 2 |
BVF Partners Portfolio Exits
48 Portfolio Exits
BVF Partners has 48 portfolio exits. Their latest portfolio exit was CTI BioPharma on June 26, 2023.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
|---|---|---|---|---|---|
6/26/2023 | Acq - P2P | 6 | |||
3/6/2023 | Acq - P2P | 4 | |||
2/3/2023 | IPO | Public | 23 | ||
Date | 6/26/2023 | 3/6/2023 | 2/3/2023 | ||
|---|---|---|---|---|---|
Exit | Acq - P2P | Acq - P2P | IPO | ||
Companies | |||||
Valuation | |||||
Acquirer | Public | ||||
Sources | 6 | 4 | 23 |
BVF Partners Partners & Customers
1 Partners and customers
BVF Partners has 1 strategic partners and customers. BVF Partners recently partnered with Ligand Pharmaceuticals on May 5, 2010.
Date | Type | Business Partner | Country | News Snippet | Sources |
|---|---|---|---|---|---|
5/21/2010 | Partner | United States | As part of this transaction and a result of BVF 's contributions , Ligand Pharmaceuticals Incorporated entered into a separate agreement with BVF and certain of its affiliates , whereby BVF and Ligand Pharmaceuticals Incorporated will share the purchase price and any proceeds from the deal equally . | 1 |
Date | 5/21/2010 |
|---|---|
Type | Partner |
Business Partner | |
Country | United States |
News Snippet | As part of this transaction and a result of BVF 's contributions , Ligand Pharmaceuticals Incorporated entered into a separate agreement with BVF and certain of its affiliates , whereby BVF and Ligand Pharmaceuticals Incorporated will share the purchase price and any proceeds from the deal equally . |
Sources | 1 |
BVF Partners Team
3 Team Members
BVF Partners has 3 team members, including , .
Name | Work History | Title | Status |
|---|---|---|---|
Mark Lampert | Founder | Current | |
Name | Mark Lampert | ||
|---|---|---|---|
Work History | |||
Title | Founder | ||
Status | Current |
Loading...